Autopsy report · NCT05037266

Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen

“The study was stopped due to lack of inclusions”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 27 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Sponsor type

University, hospital or other

Conditions

Healthy Volunteers

Interventions

COVID-19 Vaccine Janssen (Ad26.COV2-S)

Participants

27

Sites

10

Countries

France

Trials that died the same way

• Fluorescence Angiography: Planning and Monitoring of Perforator Flaps
  “The study was stopped due to lack of inclusion” (99% match in meaning)
• New Prophylactic Maneuver: the "Pushing" Maneuver, Aiming to Reduce the Risk for Shoulder Dystocia
  “the study stopped due to the lack of inclusion.” (93% match in meaning)
• Oxygen Therapy in Cystic Fibrosis
  “lack of inclusion in the study” (84% match in meaning)
• A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
  “The study was ended due to a lack of recruitment” (78% match in meaning)
• Bioavailability of Voriconazole
  “no eligible patients; study stopped without inclusion” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.